Review Mechanisms and prevention of restenosis: from experimental models by Christophe Bauters et al.
Gdovascular 
Research 
Cardiovascular  Research  31 (19%) 835-846 
Review 
Mechanisms and prevention of restenosis: from experimental models 
to clinical  practice 
Christophe Bauters * , Thibaud Meurice, Martial Hamon, Eug&ne  McFadden, 
Jean-Marc  Lablanche, Michel E. Bertrand 
Service  de Cardiologie  B et Himodynamique,  Hbpital  Cardiologique,  Boulevard  du Professeur  J. Leclercq,  59037 Lille  Cedex, France 
Received 19 October 1995;  accepted  2 February 19% 
Keywords:  Coronary angioplasty; Restenosis;  Hyperplasia; Smooth muscle cell proliferation; Platelets; Growth factors 
1. Introduction 
Percutaneous  transluminal coronary angioplasty (PTCA) 
was first  introduced by Andreas Gruentzig in  1977 [l]  as 
an  alternative  form  of  myocardial  revascularization for 
patients with  coronary  artery  disease. During  the  early 
years of its application, PTCA was limited to patients with 
single proximal coronary artery disease,  well preserved  left 
ventricular function,  and stable angina refractory to medi- 
cal treatment. Almost  twenty  years later, PTCA has be- 
come a well established  technique for myocardial revascu- 
larization of patients with unstable angina [2], patients with 
an evolving  myocardial infarction [3], patients with  multi- 
vessel disease  [4], and patients with depressed  left ventric- 
ular  function  [5].  However,  PTCA  remains limited  by 
restenosis  that occurs in  30-60%  of cases  despite a suc- 
cessful procedure [6-g].  Assuming 500000 PTCA proce- 
dures per year in the United States  [lo],  more than 150000 
patients develop  restenosis every  year.  Although  some 
restenoses  may be silent,  most of  these patients present 
with  recurrent angina  and a  significant  proportion  will 
need a new revascularization procedure. Decreasing the 
rate of restenosis would sharply lower the long-term cost 
of PTCA; in the United States,  a reduction of the rate of 
restenosis  from an hypothetical 33% to 25% might save as 
much  as $750 million  annually  [IO].  Numerous agents 
have been used to prevent restenosis, and the results of 
more than 40 multicenter randomized clinical  trials have 
now been published [11,12]. Despite intensive investiga- 
tion in this area, no pharmacological therapy has yet been 
found to be useful in preventing restenosis.  The purpose  of 
this report is twofold:  first, to review the available infor- 
mation  relevant  to  the  mechanisms of  restenosis, and, 
second,  to review the strategies  currently being explored as 
possible approaches  to the control of coronary restenosis 
after PTCA. 
2. Mechanisms of restenosis 
2.1.  The healing  process afrer  arterial  injury 
2.1 .I.  Neointimal  hyperplasia 
In  response to  experimental  arterial  injury,  medial 
smooth muscle cells @MC) shift  from a contractile to a 
synthetic phenotype,  proliferate, migrate, and produce large 
amounts of  extracellular  matrix  (Fig.  1).  This  growth 
response  leads to the development  of a neointimal thicken- 
ing also known as neointimal hyperplasia [13] (Fig. 2). 
Immediately after arterial injury with a balloon catheter, 
multiple  factors (see below)  lead  to  the  activation  of 
SMCs. Early markers of SMC activation such as expres- 
sion of nuclear oncogenes  are detectable  as soon as 30 min 
after injury  [ 14,151.  Induction  of  c-fos, c-jun,  and c-myc 
proto-oncogenes  is one of the earliest transcriptional events 
associated with  growth  factor  stimulation  [16]  and  the 
increased  expression of these genes  is a transient response 
to mitogenic stimulation persisting at most for a few hours 
after exposure to growth factors [17]. It has been recently 
demonstrated  that the distribution of  clfos and c-jun prod- 
ucts after arterial injury  was concentrated  in smooth mus- 
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Fig.  1. The  cascade of  events leading to  neointimal  thickening after 
balloon  denudation. SMC = smooth muscle cell.  ECM = extracellular 
matrix. 
cle cell nuclei [15]. The corresponding oncoproteins bind 
to a specific DNA  sequence  of target genes to stimulate 
their transcription and are involved in the Gl  phase  of the 
cell  cycle [16]. Experiments in  cell  culture models have 
shown that  the use of  antibodies or  of  antisense RNA 
against nuclear oncogenes prevents cell  entry  into  the S 
phase and the subsequent  synthesis of DNA  [18,19]. It  is 
therefore plausible  that this  expression of  nuclear onco- 
genes  in the hours following  angioplasty is associated  with 
the early Gl  events preceding DNA  synthesis in  smooth 
muscle cells. Recently, the use of  antisense oligonucleo- 
tides  against nuclear  oncogenes was  shown  to  inhibit 
neointimal  thickening  in  vivo  in  various  animal models 
[20,21], suggesting that the inhibition  of  this early phase 
can significantly  affect the cascade  of  events leading to 
neointimal hyperplasia a few weeks later. 
Activation  of  SMCs is associated  with  a shift  from a 
contractile to a synthetic phenotype [22-241 and leads to 
proliferation, migration, and synthesis of extracellular ma- 
trix.  Proliferation  of  medial SMCs is evident 24 h  after 
experimental balloon  injury  and continues for  at least 2 
weeks [25].  At  least  20  to  40%  of  medial  SMCs  are 
activated and enter the cell cycle between 24 h and 3 days 
after balloon denudation [26]; these cells then migrate to 
the intima through breaks in the internal elastic membrane. 
Many of these neointimal cells continue to proliferate for 
several cycles but nearly half of the migrating cells do not 
synthes:ize  DNA  [26]. Proliferation and migration  should 
thus be considered as two distinct mechanisms  leading to 
neointimal  thickening;  as discussed  below,  some factors 
may affect SMC migration but have no effect on  SMC 
proliferation,  and vice versa [27]. 
In  animal models, the degree of  intimal  thickening  is 
maximal  after 3 months [28]; the additional volume that 
accumulates after 2  to  4  weeks reflects the  adjunctive 
synthesis of extracellular matrix by synthetic SMCs [22- 
24,291.  Experimental balloon denudation is followed by a 
marked increase in  expression of the genes that code for 
collagen and elastin in the arterial wall [30]. Similarly,  the 
reexpression of embryonic forms of fibronectin occurs in 
the media and adventitia of rabbit arteries 24-48  h  after 
injury;  two  weeks after  balloon  denudation, when  the 
neointima  is formed, fibronectin  mRNAs as well  as the 
fibronectin protein accumulate  in the luminal layers of the 
neointima  [31]. As  pointed out by  Schwartz et  al.  [32], 
cellular components  constitute only about 11% of neointi- 
ma1 volume,  and the  remainder is  extracellular  matrix. 
Given the abundance  of extracellular matrix  in  restenotic 
lesions, one potential “anti-restenosis”  strategy would be 
to  reduce the  matrix  volume  surrounding each cell;  a 
substantial reduction in  neointimal volume might  be ob- 
tained  without  the  need to  inhibit  SMC  migration  or 
proliferation. 
After  2  to  3  months, SMCs return  to  a  contractile 
phenotype and no  further  significant  increase in  intimal 
thickening occurs [33]. 
2.1.2.  Arterial  remodeling 
Arterial remodeling is well described  in de novo athero- 
sclerosis. Glagov et al. [34] observed  that human coronary 
arteries undergo adaptive enlargement in response  to pro- 
gressive plaque expansion and maintain  the lumen  area 
until  the plaque occupies  40% of the area  circumscribed by 
Fig. 2. Histological cross  sections  of rabbit iliac arteries.  Left: control (non-denuded)  artery. Right: iliac artery 28 days after balloon denudation.  The arrow 
indicates the internal elastic lamina. A = adventitia; M = media; NI = neointilna. 
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the internal elastic lamina. This compensatory  enlargement 
may thus limit  the effect of plaque development on lumen 
narrowing. 
There is increasing experimental evidence that neointi- 
ma1 hyperplasia is  not  the  sole mechanism leading  to 
lumen renarrowing after angioplasty, and that arterial re- 
modeling also plays a major role in this process  [35-371. 
In  the hypercholesterolemic rabbit  model, Kakuta et  al. 
[36] showed that compensatory enlargement of the vessel 
(increase in  internal  elastic  lamina  area) occurs in  the 
weeks following  experimental  angioplasty;  this  process 
was able to  accomodate nearly  60%  of  the  neointimal 
formation in  response to balloon  injury  and limit  lumen 
narrowing.  Surprisingly,  restenosis was  not  related  to 
neointimal  formation but  to  a lack of  compensatory en- 
largement or even to some degree of vessel constriction. 
Vascular remodeling is  thus  able to  limit  the effect of 
neointimal formation on chronic lumen diameter and dif- 
ferences  in vascular remodeling, not differences in intimal 
formation,  account for  restenosis in  this  model.  Other 
reports by Post et al. [35] and Lafont et al. 1371  have also 
demonstrated the  role  of  vascular remodeling  in  other 
models of restenosis. 
2.2. Mechanisms  of restenosis  in  humans 
One important question is whether the pathophysiologi- 
cal mechanisms  of restenosis  demonstrated  in experimental 
models also apply to the clinical  situation. Obviously the 
arterial wall response  after coronary angioplasty in humans 
is less well documented  than the responses  in experimental 
models. Nevertheless,  histological studies have shown that 
intimal  thickening in  the restenotic lesion contains SMCs 
in an abundant  extracellular matrix [38-401. Immunohisto- 
chemical  studies  [41,42]  have  documented phenotypic 
modulations of SMCs after PTCA in humans; during the 2 
months following  PTCA, SMCs are in a synthetic pheno- 
type and thereafter they revert to a contractile phenotype. 
Various degrees  of proliferation have been demonstrated  in 
atherectomy specimens from  restenotic lesions  [43,44]. 
Migration  of  SMCs has never been demonstrated after 
PTCA in humans; it should be noted, however, that in man 
there is not necessarily a need for SMC migration into the 
intima  since SMCs  are  already  present in  the  athero- 
sclerotic plaque. 
However, as in experimental models, neointimal hyper- 
plasia is not the sole mechanism of restenosis  in humans. 
There  is  preliminary  intracoronary  ultrasound  evidence 
that vascular remodeling also occurs after angioplasty in 
humans [45,46]. Studies by Mintz  et al. [45,46] suggested 
that most of the late lumen loss after balloon angioplasty 
was due to arterial remodeling and not to intimal  forma- 
tion.  The  contribution  of  remodeling to  restenosis after 
nonballoon coronary angioplasty may, however, be differ- 
ent. Coronary stenting, for  example, may eliminate  any 
Fig.  3. Reendothelialization after balloon denudation. Regenerated  en- 
dothelium was identified by immunostaining with platelet-endothelial  cell 
adhesion-l (PE~~h4-1/~-31)  related antigens. Left: incomplete reen- 
dothelialization; Right: complete reendothelialization. 
component of  arterial remodeling, either enlargement or 
constriction (see below). 
2.3. Potential  regulators  of the healing  process 
2.3.1.  The endothelium 
The endothelium plays a fundamental role in controlling 
vessel tone  and  SMC  proliferation.  After  experimental 
angioplasty, reendothelialization  of  the  denuded surface 
occurs within  weeks and may be either complete  [47,48] or 
incomplete  [49-511  depending upon  the  animal  model 
studied (Fig.  3); areas  where the endothelial covering has 
rapidly  regenerated  have less marked intimal  thickening 
than  areas where  endothelial  regeneration occurs later 
[49,52,53]. Endothelial regeneration is probably delayed or 
may even be incomplete in humans. In one study, Gravanis 
and  Roubin  [54]  did  not  find  endothelial  cells  at  the 
angioplasty site in  patients who died within  1 month of 
PTCA  but  found  substantial reendothelialization  in  the 
later specimens.  Previous experimental studies support the 
notion that certain functions of the endothelium -  includ- 
ing  barrier  regulation  of  permeability,  thrombogenicity, 
and leukocyte adherence,  as well as production of growth- 
inhibitory  molecules -  are critical  to the prevention of 
luminal  narrowing by  neointimal thickening [55-571. Ni- 
tric oxide (NO) has been identified as one of the relaxant 
factors synthesized and released by  normal endothelium 
158,591.  NO may theoretically interact with the process  of 
restenosis at several levels. First,  NO  has an inhibitory 
effect on platelet adhesion and aggregation 1601;  second 
NO has an inhibitory  effect on SMC proliferation [56,61]; 
third, NO may exert a beneficial effect on arterial remodel- 
ing [62]. When L-arginine, the physiological precursor of 
NO,  was administered to  animals before endothelial de- 
nudation, the degree of subsequent  neointimal thickening 
was significantly  reduced compared to  that observed in 
control animals that did not receive r.,-arginine  [55,63,64]. 
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2.3.2.  Platelets  and  the thrombotic  process 
Immediately after experimental balloon injury, endothe- 
lial  denudation induces platelet adhesion and aggregation 
resulting in release  of the constituents of their alpha gran- 
ules .within  a  few  minutes [7,65].  Numerous mitogenic 
substances,  including PDGF (Platelet Derived Growth Fac- 
tor),  are thus released at the site of  injury  and may be 
involved  in  the process of  SMC activation  [66]. Experi- 
ments  performed  in  thrombocytopoenic  animals  have 
demonstrated  the fundamental role of platelets in determin- 
ing the extent of neointimal thickening  following  arterial 
injury  [67]. In  a canine model of  endothelial injury,  the 
intensity of cyclic flow  variations related to platelet accu- 
mulation was a major determinant of neointimal thickening 
[68]. Recent studies have shown that thrombocytopoenia 
inhibits migration of activated SMCs from the media to the 
intima but has no effect on the initial  cycle of cell prolifer- 
ation [65]. Coagulation proteins such as thrombin may also 
be implicated in the response  of SMCs [69]. Thrombin has 
mitogenic properties for SMCs [70] and has been demon- 
strated to induce multiple  growth-related signals in SMCs 
including the expression of the c-fos proto-oncogene  [71]. 
Finally, the volume of thrombus at the PTCA site may also 
play a role in the subsequent  restenotic process.  An alter- 
native  proposal for  the  cellular  mechanisms leading  to 
neointimal  hyperplasia  has  been  recently  advanced by 
Schwartz et al. [32]; this hypothesis based on the porcine 
coronary injury  model suggests  that the volume of intra- 
coronary thrombus at the time of PTCA may determine the 
subsequent  volume of neointima. 
In  humans, the presence of  thrombus at the time  of 
PTCA can be assessed  using angioscopy [72]. We recently 
reported the relation of angioscopic findings at the time of 
PTCA to subsequent  restenosis [73]. Patients who had a 
luminal tbrombus at the PTCA site had a much higher risk 
of  restenosis than  patients without  thrombus. Similarly, 
when PTCA  is  performed in  patients with  an  unstable 
coronary syndrome, a situation where intraluminal  throm- 
bus plays a major role [74], the risk of restenosis  appears 
higher  than that observed when PTCA  is  performed in 
patients with  stable angina [75,76]. 
2.3.3.  Growth  factors 
Growth  factors released at  the  site  of  injury  play  a 
major role  in  the response of  SMCs to  balloon  injury. 
Platelets are an important source of PDGF, but endothelial 
cells,  macrophages, and SMCs may  themselves secrete 
PDGF after arterial injury  [22,77-791. PDGF seems  to be 
critical for SMC migration from media to intima, whereas 
its absence  does  not limit  SMC proliferation [65,80]. Using 
an antibody to  PDGF, Ferns et al.  were able to  reduce 
neointimal  SMC  accumulation after experimental angio- 
plasty without  affecting mitogenic activity  [80]. Basic fi- 
broblast growth factor (bFGF), an in-vivo  angiogenic fac- 
tor [Sl]  with  proliferative  properties for  both SMCs and 
endothelial cells  through  specific receptors [82,83], may 
also play  a role  in  restenosis. SMCs within  the tunica 
media, when damaged by  an oversized balloon, may re- 
lease bFGF due to  stretch or  crush injury;  the liberated 
bFGF can then mediate the initial  wave of  cell  division 
within  this  layer  of  the  blood  vessel. Infusion  of  an 
antibody that neutralises bFGF reduces the first  cycle of 
SMC  replication  by  up  to  80%  in  the  arterial  media 
following  balloon  denudation but  has no  effect on  the 
resulting  neointimal  thickening  [84].  Among  the  other 
growth factors that may participate in  the restenotic pro- 
cess  are transforming growth factor p  (TGFp)  and insulin 
growth factor type 1 (IGF-1). TGFP mRNA is increased  in 
SMCs following  arterial wall  injury  and reaches a maxi- 
mum before the phase of  extracellular  matrix  synthesis 
[85,86]. TGFP  is known  to modulate fibronectin  expres- 
sion [87] and may be important in the control of extracellu- 
lar matrix synthesis [88,89]. TGFP is produced by SMCs, 
platelets and endothelial cells [77,90]. The main source of 
IGF-1  is  SMCs and its  mRNA  expression undergoes a 
lo-fold  increase in  the weeks following  balloon denuda- 
tion [91]. 
2.3.4.  Hormonal  factors 
The renin-angiotensin-aldosterone  axis has been impli- 
cated in  the patbogenesis  of  restenosis [92,93]. There is 
evidence that angiotensin II  may modulate SMC growth in 
vitro [94,95]; angiotensin II  infusion in rats is followed by 
marked SMC proliferation  in the intima [%I.  Powell et al. 
have  reported that  inhibitors  of  angiotensin converting 
enzyme  (ACE) suppress  myointimal proliferation after vas- 
cular injury [97]. The actions of ACE inhibitors are proba- 
bly not solely related to an effect on angiotensin II  levels 
but  may  in  part  be  due  to  an  effect  on  bradykinin 
metabolism  [98,99] or to an effect mediated  by aldosterone 
[lOOI. Serotonin and other vasoactive hormones (catechol- 
amines, vasopressin) released at the angioplasty site are 
also  able  to  induce  SMC  proliferation  [ lOl-  1041. Re- 
cently,  considerable interest has  also  been focused on 
endothelin, a potent vasoconsttictor peptide produced by 
vascular endothelial cells [105]. Endothelin binds specifi- 
cally  to human SMCs in  culture and can induce nuclear 
oncogene  expression  [106,107]. Endothelin has been shown 
to have mitogenic activity  for rat aortic SMCs [lOS] and 
endothelin antagonists reduce neointimal  thickening  after 
vascular injury  in vivo  [109,1101. 
2.3.5. Mechanical  factors 
Mechanical factors may also play a role in the degree  of 
restenosis  in experimental models. Large areas  of endothe- 
lial  denudation without  trauma to the media lead to mild 
neointimal thickening despite late endothelial regeneration 
[ 1111;  in  contrast, focal endothelial denudation with  sub- 
stantial medial trauma, combined with rupture of the inter- 
nal elastic lamina, is  associated with  marked neointimal 
proliferation,  although the endothelium regenerates  within 
a few  days [112]. These results suggest that endothelial 
b
y
 
g
u
e
s
t
 
o
n
 
N
o
v
e
m
b
e
r
 
3
,
 
2
0
1
4
D
o
w
n
l
o
a
d
e
d
 
f
r
o
m
 C. Bauters  et al./  Cardiovascular  Research  31 (1996)  83.5446  839 
denudation alone is not sufficient to produce major neointi- 
mal thickening  and that direct injury  of SMCs is also an 
important  factor.  Direct  injury  to  SMCs may  induce  a 
greater neointimal  response by  (1)  increasing the  local 
release  of growth factors by necrotic SMCs, and (2) activa- 
tion of intracellular pathways leading to SMC proliferation 
[113,114]. 
heparin [ 1291  and l-  to 3-month treatment with  subcuta- 
neous  low molecular weight heparin [ 1301  have been shown 
to be inneffective. Recent clinical  trials have evaluated the 
more powerful  antithrombin  hirudin;  hirudin  inhibits  ex- 
perimental  restenosis [131]  but  does not  appear to  be 
effective in humans [ 1321. 
Beside acute mechanical factors, chronic  mechanical 
factors may also play  a role. Blood  flow  in  the injured 
vessel may  be  a  determinant of  subsequent restenosis; 
experimental studies by  Kohler  et al. have demonstrated 
greater neointimal  hyperplasia in  the case of  decreased 
blood flow  after angioplasty [ 115,116]. 
3.1.3. ACE  inhibitors 
3. Prevention  of  restenosis 
3.1.  Discrepancies  between  experimental  models  and  hu- 
man restenosis 
A  potential  role  for  angiotensin  converting  enzyme 
(ACE) inhibitors  in the limitation  of neointimal prolifera- 
tion has been suggested,  based on the demonstration that 
angiotensin II  plays an important  role  in  the control  of 
SMC growth [96]. After initially  positive results in experi- 
mental models [97], two  large clinical  studies (MERCA- 
TOR  and MARCATOR),  with  over 2000 patients com- 
bined, examining the ACE inhibitor  cilazapril  have failed 
to  show  any  significant  impact  on  restenosis rates 
[133,1341. 
3.1.4.  Lipid-lowering  agents 
A large number of pharmacologic trials have examined  Lovastatin, which  blocks the production of  mevalonic 
whether systematically administered  pharmacologic agents  acid  and the  synthesis of  cholesterol by  inhibiting  the 
reduce the risk of angiographic restenosis  [ 11,12,117].  The  enzyme HMG-Co A reductase,  has been shown to inhibit 
overwhelming  majority  of  these clinical  pharmacologic  both cell proliferation  in culture [ 1351  and restenosis  after 
studies reported to date have failed to show a significant  balloon angioplasty in rabbits [ 1361.  In humans, however, a 
reduction in  the incidence of restenosis  in humans. These  large  double-blind  placebo-controlled  trial  has  recently 
results  are  in  sharp contrast with  the  often  promising  been published showing, again, no benefit of the treatment 
results obtained in experimental models [ 1181.  in the prevention of restenosis  [ 1371. 
3.1 .I.  Platelet  antagonists 
Platelet adhesion and activation is an important step in 
vascular healing  during  the first  days after angioplasty. 
Friedman et  al.  [67]  noted  suppression of  the  intimal 
proliferative response  to balloon injury  in severely throm- 
bocytopenic rabbits. Faxon et al. [119] observed a reduc- 
tion in  the incidence and severity of recurrent stenosis in 
the atherosclerotic rabbit  model in  animals treated with 
sulfinpyrazone or  aspirin  and dipyridamole.  In  humans, 
aspirin, the prostacyclin analogue  ciprostene, the serotonin 
antagonist  ketanserin, and several  thromboxane A,  antago- 
nists have been studied [120- 1251.  While antiplatelet agents 
have significantly  reduced the risk of acute closure, there 
is  no  evidence that  they  may  reduce restenosis. More 
recently, the glycoprotein receptor antibody GP IIb/IIIa 
has been shown to reduce clinical  events 6 months after 
PTCA [ 1261;  angiographic studies are currently being per- 
formed to  analyze the impact of  these very  potent an- 
tiplatelet agents  on restenosis. 
Fish oils containing omega-3 fatty  acids may decrease 
LDL  cholesterol,  increase HDL  cholesterol,  and  alter 
platelet functions [138]. Several randomized clinical  trials 
have been performed to examine if  omega-3 fatty  acids 
can reduce restenosis  and have provided conflicting results 
[139-1421. 
3.1 S.  Growth  factor  inhibitors 
3.1.2.  Anticoagulants 
Heparin  is  one of  the molecules that has been most 
widely  used in  experimental models of  restenosis. Both 
non-fractionated heparin  and  the  newer  low  molecular 
weight derivatives have demonstrated  antiproliferative  ac- 
tivity  in  animal  models such as the rat  and the rabbit 
[26,127,128]. However, in humans, short-term intravenous 
Several growth  factor  inhibitors  such as trapidil  and 
angiopeptin have been tested in the prevention of resteno- 
sis. Trapidil  is a platelet-derived growth factor antagonist 
shown to be effective in experimental models of restenosis 
[143]. Two trials have suggested  that trapidil  may have an 
effect  on  restenosis, and further  study  of  this  agent is 
warranted [ 144,145]. Angiopeptin,  a synthetic cyclic  oc- 
tapeptide analogue of  somatostatin, has been shown to 
reduce neointimal hyperplasia in  several different animal 
models of  angioplasty [ 146,147]. The mechanism of  this 
effect is unknown but is thought to be related to a local 
inhibition  of growth factors responsible for smooth muscle 
cell activation [146,148]. We have recently shown that, in 
a rabbit model of  balloon  denudation, pretreatment with 
angiopeptin is associated  with a marked inhibition  of c-fos 
and c-jun  expression 30 min after injury  and with a highly 
significant reduction in neointimal thickening 28 days after 
injury [ 1491.  By contrast, if  angiopeptin treatment is begun 
1 h  after injury,  no  effect  on  neointimal  thickening  is 
observed.  These findings  suggest  that the inhibitory  effect 
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of  angiopeptin  in  this  model  may be,  at  least in  part, 
related to an inhibitory  effect on early (Gl)  events of the 
cell  cycle. In  humans, however, two large clinical  trials, 
one in Europe and one in the United States,  have recently 
been reported to  show no  effect  of  angiopeptin in  the 
prevention of restenosis  [ 150,15  11. 
3.1.6. Other agents 
Many  other  agents have been evaluated as potential 
inhibitors  of  restenosis.  Calcium  channel  antagonists 
[ 152,153], corticosteroids [ 1541,  and colchicine [ 1551  have 
failed  in  man in  spite of encouraging results in  animals. 
Recently, the results of  the  ACCORD  study [ 1561 sug- 
gested that molsidomine, a direct NO donor, may signifi- 
cantly  reduce the  risk  of  angiographic restenosis; these 
results are in  agreement with  the potential beneficial ef- 
fects of NO donors on the restenotic process  (see above). 
Further studies are needed with  these agents to confirm 
this finding. 
In  summary, in  spite of encouraging results in  animal 
models, no systemic pharmacologic agent has been shown 
conclusively  to produce a clinically  worthwhile  reduction 
in restenosis  after PTCA. There are at least four potential 
explanations for these discrepancies. 
A first explanation might be inter-species  differences; a 
drug that inhibits  neointimal thickening  in  rats or rabbits 
will  not  necessarily achieve the same effect in  humans. 
This possibility has led to attempts  to develop more repre- 
sentative models of restenosis, in particular the pig model 
[ 157,158]. Recently, however, various drugs such as an- 
giopeptin 11471  have been found to be effective in the pig 
model but not in humans [ 150,15  1  I suggesting  that the pig 
model will  not be superior to previously developed  models 
in  terms of  prediction  of  inhibition  of  restenosis in  hu- 
mans. 
Secondly, many clinical  trials have used low  doses or 
inadequate duration  of  therapy  that  can  also limit  the 
ability  to  obtain  positive  results even with  an effective 
drug. Very  high  doses of  drugs have been necessary  to 
inhibit  restenosis in  experimental models and in  most ‘of 
the negative clinical  trials  the doses utilized  were much 
lower. The inhibition  of experimental restenosis  with ACE 
inhibitors,  for example, has been achieved with  doses of 
drugs 10-100 times higher than the doses  that can be used 
in humans [97,133,134]. This has prompted interest in the 
potential role of  locaily  delivered drug (see below). This 
method would allow the local release  of greater quantities 
of drug while minimizing  systemic effects. 
Third, pretreatment  before PTCA may also be an impor- 
tant  issue. As  already  discussed above, drugs  such as 
angiopeptin or ACE inhibitors  can significantly  inhibit  the 
early (15-30  min)  phase of  the SMC response  to injury 
[149,1591;  this  suggests that when using these agents in 
humans,  pretreatment  may increase  the effectiveness  of the 
therapy. 
Finally,  most of the “anti-restenosis”  therapies tested 
so far have been directed against neointimal hyperplasia. 
As discussed  above, neointimal hyperplasia is not the sole 
mechanism of restenosis  after conventional balloon angio- 
plasty in  humans and recent studies have suggested  that 
late vessel constriction  may be the major factor. Future 
studies will  try to provide a better understanding of vessel 
remodeling  and to  identify  drugs that might  affect this 
process. In  1995, however, the use of  alternative tech- 
niques of  endovascular revascularization was increasing. 
Recent studies have  shown that  coronary stenting may 
significantly  decrease  the incidence of restenosis  compared 
to  balloon  angioplasty [ 160,161]. The  mechanism(s) of 
restenosis within  coronary  stents may  also be different 
from  that of  restenosis after conventional balloon  angio- 
plasty; this implies that a treatment shown to be ineffective 
in preventing restenosis  after PTCA will  not necessarily  be 
ineffective in preventing restenosis  after coronary stenting 
(see Section 3.3). 
3.2. Local drug-delivery 
3.2.1. How to deliver? 
In  recent years, a variety  of  balloon catheter systems 
have been designed  to allow the local delivery of therapeu- 
tic  agents at the site of  arterial injury.  The first  devices 
were the double-balloon infusion catheter and the Wolinky 
balloon catheter [162] (a perforated balloon allowing high 
pressure infusion  of  fluids  into  the  vessel wall).  More 
recently, other delivery systems  such as  the hydrogel-coated 
balloon catheter [ 1631  or the dispatch catheter [ 1641  have 
been made available. 
3.2.2. What to deliver? 
3.2.2.1. Anti-proliferative  drugs. Most of the antiprolifera- 
tive  drugs that have been effective in  preventing experi- 
mental restenosis are potential candidates  for  the preven- 
tion  of  restenosis using  local  drug-delivery  systems. As 
stated  before, this approach  may allow the local release  of 
high quantities of drug while minimizing  systemic effects. 
However, an important limitation  of this technique is the 
rapidity  with  which  the  infused drug  leaches from  the 
arterial wall,  and the short duration of therapeutic efficacy 
of this approach. In experimental models, high drug levels 
persist for less than 48 h  after drug infusion  [162]. It  is 
probable, therefore, that if this approach  is to be effective, 
it  will  be necessary  either to use drugs that will  interfere 
with  the early steps of the restenotic process -  such as 
angiopeptin [149,165] -  or to develop a means  by which 
drug efflux  from  the arterial wall  can be retarded. One 
potential means  of achieving this would be the delivery of 
drug-impregnated  biodegradable  microspheres  into the ves- 
sel wall  to  obtain  a more prolonged local  drug activity 
[166,167]. 
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3.2.2.2.  Gene therapy.  One genetic approach  to the goal of 
inhibiting  the smooth muscle cell response  to injury  is the 
use of antisense  oligonucleotides. A  single-stranded  DNA 
sequence  that is complementary to  a known  region of  a 
particular  mRNA  is  synthetized. Following  introduction 
into cells, the DNA  strand binds specifically to the com- 
plementary nucleic acids; the double-stranded  DNA-RNA 
hybrid  is then degraded.  In  most of the antisense studies 
performed to inhibit  restenosis,  the target gene has been a 
nuclear  oncogene; c-myb [20]  or  c-myc [21]  antisense 
oligonucleotides delivered in  a site-specific manner inhib- 
ited smooth muscle cell accumulation at the site of injury 
when inspected  a few weeks after treatment. Clinical  trials 
will  soon be designed to study the effect of local delivery 
of antisense  oligonucleotides after PTCA in humans. 
Another approach  is to transfect locally a gene that may 
inhibit  the restenotic process.  Experimental studies  by Steg 
et al. [168] have demonstrated  efficient gene transfer into 
the vascular wall using percutaneous  delivery of an aden- 
oviral  vector;  they  also showed that when administered 
with  appropriate catheters the  level  of  transfection  of 
extravascular organs was very low. The expression of the 
gene was transient (a few weeks) but this may not neces- 
sarily be a limitation  in this indication. The question of the 
gene to be tmnsfected  remains to be answered;  recently, in 
vivo gene transfer of nitric  oxide synthase  has been shown 
to inhibit  neointima formation in injured rat carotid arteries 
[169]. 
3.2.2.3.  Indirect  approach.  Most of the “anti-restenosis” 
strategies are based on  a  direct  inhibition  of  the  SMC 
response  to injury.  Another strategy, the indirect approach, 
has recently been suggested.  Asahara et al. demonstrated 
that a single local  administration of  vascular endothelial 
growth factor (VEGF) is sufficient to facilitate endothelial 
repair in a rat model of balloon injury  [170]; in this study, 
the  degree of  neointimal  thickening  at  2  weeks and 4 
weeks after balloon injury  was correspondingly attenuated 
to a statistically significant degree in arteries treated with 
VEGF versus controls. These results are probably related 
to the inhibitory  effect of the endothelium on SMC growth 
[56,61]. 
3.3. Mechanical  prevention 
During  the past several years, “new”  angioplasty de- 
vices including  atherectomy techniques, and stents have 
expanded the indication  for  angioplasty to  patients with 
anatomy considered suboptimal for  conventional PTCA. 
With  these devices came the hypothesis that creating a 
more satisfactory immediate result would reduce the risk 
of subsequent  restenosis. 
There are two  main  mechanical atherectomy devices 
with  sufficient clinical  experience to evaluate their poten- 
tial to limit  restenosis:  rotational atherectomy  (the Rotabla- 
tar)  and directional coronary atherectomy. Although  ran- 
domized studies are still  needed, the rates of  restenosis 
observed with the Rotablator do not appear  to be substan- 
tially  lower  than that observed after conventional PTCA 
[ 171,172]. It  must be pointed out that adjunctive balloon 
angioplasty is now performed in the majority of cases  after 
rotational atherectomy  in order to achieve the largest possi- 
ble acute gain; this may offset the theoretical benefits of 
the  Rotablator (i.e.,  preferential  ablation  of  fibrous  or 
calcified tissue with  minimal damage  to normal structures 
[ 1731). Directional  coronary  atherectomy @CA)  effec- 
tively  removes atherosclerotic tissue but  also frequently 
constituents of the normal vascular wall [174]. DCA allows 
a higher acute luminal  gain than conventional PTCA, the 
late  luminal  loss,  however,  is  also  higher  after  DCA 
suggesting  that atherectomy  may stimulate the proliferative 
process  [ 1751.  Recently, the one year follow-up  of patients 
randomized to either DCA  or F’TCA has demonstrated  a 
significantly  higher mortality  in  patients treated by DCA 
[176];  although  the  mechanism(s) of  this  unfavorable 
long-term effect is unknown, these results may limit  the 
use of this technique of revascularization in humans, 
The coronary stems currently under clinical  evaluation 
are metallic  devices that are implanted permanently into 
the vessel wall  [177,178]. Recent studies have shown that 
implantation of an intracoronary stent in conjunction with 
balloon angioplasty is not only highly  effective in treating 
acute vessel closure due to balloon-induced dissections, 
but  may  also reduce the  risk  of  restenosis. Two  large 
randomized  trials,  the  Benestent study  and  the  Stent 
Restenosis  Study (STRESS)  have been recently completed 
and  published  [160,161]. Both  trials  showed that  at  6 
months the need for  repeated revascularization (the pri- 
mary  clinical  end point)  was reduced with  stenting, as 
compared with  standard angioplasty. The rates of  angio- 
graphic restenosis  were also lower in patients randomized 
to coronary stenting than in patients treated with  conven- 
tional balloon angioplasty (22 vs 32%, respectively in the 
Benestent  trial, and 32 vs 428,  respectively in the STRESS 
trial.  These angiographic results were mainly related to a 
larger increase in  the diameter of the lumen immediately 
after stenting. In  spite of  a significantly  higher late loss 
during  follow-up  in  the stent groups, the net result at 6 
months was still  better with  stenting than with  standard 
angioplasty. 
The mechanism of restenosis  within  coronary stems is 
not  completely  understood but  preliminary  intravascular 
ultrasound  studies [179]  suggest that  coronary  stenting 
effectively  prevents vessel constriction  and that most of 
the late luminal  loss occurring after stent implantation is 
due to plaque growth (probably related to neointimal hy- 
perplasia). This  observation, taken together with  the fact 
that the late luminal  loss after coronary stenting is almost 
two  times higher  than  that observed after conventional 
balloon  angioplasty, suggests  that restenosis within  coro- 
nary  stents might  be much more sensitive to  therapies 
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designed to inhibit  neointimal hyperplasia than restenosis 
after standard  angioplasty. 
Thus, the future prevention might well be the combina- 
tion  of  a  mechanical device  that  produces the  widest 
possible lumen  and prevents vessel constriction  with  a 
pharmacologic approach to  inhibit  the proliferative  pro- 
cess.  Although  systemic  administration  of  “anti- 
restenosis”  drugs  has  not  yet  been  tested to  prevent 
restenosis after coronary stenting, it  is  very  likely  that 
pharmacologic inhibition  of neointimal hyperplasia within 
coronary stents will  take advantage  of local delivery  tech- 
niques. In  addition  to  local  drug  delivery  catheters de- 
scribed above, the stent itself may be coated with polymers 
and serve as a platform for drug delivery  over relatively 
long periods of time [ 1801. 
A  remaining and important question is  whether com- 
plete inhibition  of neointimal thickening is desirable. Acute 
coronary events are mainly  the  consequence of  plaque 
rupture and thrombus  formation [74]. Proliferation of SMCs 
and matrix production after angioplasty may prevent per- 
sistent instability.  When angioscopy is  performed a few 
months after PTCA of unstable plaques [181], the angio- 
scopic appearance  is almost unvaryingly  that of  a stable 
smooth white  plaque without  thrombus. Some degree of 
neointimal thickening may thus be beneficial. If  inhibition 
of  neointimal  hyperplasia becomes feasible,  it  will  be 
important to determine how much should be inhibited. 
4. Conclusion 
In  conclusion, restenosis  remains an important clinical 
problem. The  results of  large pharmacologic trials  have 
been disappointing. Restenosis  which is now known to be 
due to both vessel remodeling and neointimal hyperplasia 
may be limited  in  the future by  a combined mechanical 
and pharmacologic approach.  The continued attractiveness 
of PTCA as an alternative to medical treatment and bypass 
surgery for patients with  coronary artery disease will  de- 
pend upon our ability  to control the restenotic process. 
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